Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 5/20 | 0.63 |
| ▸ | POR | P16435 | 4/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | RECQL | P46063 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (3R)-Dunnione SCHEMBL29468606 | 1.00 | NQO1 (0.63) | NQO1PORMEN1KMT2AKDM4E | |
| (3R)-Dunnione SCHEMBL6052903 | 0.93 | NQO1 (0.56) | NQO1PORMEN1KMT2AKDM4E | |
| Alpha-Dunnione SCHEMBL940069 | 0.88 | NQO1 (0.56) | NQO1PORMEN1KMT2AKDM4E | |
| SCHEMBL8260282 | 0.86 | NQO1 (0.52) | NQO1PORMEN1KMT2AKDM4E | |
| (3R)-Dunnione SCHEMBL8535310 | 0.83 | NQO1 (0.47) | NQO1PORMEN1KMT2AKDM4E | |
| SCHEMBL6052899 | 0.80 | NQO1 (0.67) | NQO1PORKDM4EMAPTALDH1A1 | |
| SCHEMBL6052838 | 0.79 | NQO1 (0.57) | NQO1PORMEN1KMT2AKDM4E | |
| SCHEMBL14439377 | 0.78 | NQO1 (1.00) | NQO1PORALDH1A1CYP3A4IDO1 | |
| SCHEMBL3329489 | 0.77 | NQO1 (0.50) | NQO1PORMEN1KMT2AKDM4E | |
| SCHEMBL3331249 | 0.77 | NQO1 (0.50) | NQO1PORMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-05-29 | — | — | US | claimed |
| EP-4532480-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | Cambridge Enterprise Limited (GB) | 2025-04-09 | — | — | EP | claimed |
| WO-2025030135-A2 | METHODS FOR TREATING AND AMELIORATING ANGINA, MYOCARDIAL INFARCTION, REPERFUSION INJURY, HEART ARRHYTHMIAS AND CONGESTIVE HEART FAILURE (CHF) | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-06 | — | — | WO | claimed |
| WO-2025029578-A1 | SUMOYLATION AS A THERAPEUTIC TARGET IN INFLAMMATORY BOWEL DISEASES AND INFECTIONS DISORDERS | DUKE UNIVERSITY (US) | 2025-02-06 | — | — | WO | claimed |
| WO-2024249339-A1 | COMBINED RTK AND SUMO INHIBITION FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-05 | — | — | WO | claimed |
| CN-119033774-A | KL1333 composition and application thereof in preparation of tumor treatment drugs | 澳门大学 | 2024-11-29 | — | — | CN | claimed |
| US-20240358731-A1 | SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA | NORTHEASTERN UNIVERSITY | 2024-10-31 | — | — | US | claimed |
| WO-2023246464-A1 | USE OF CRYPTOTANSHINONE SUBSTANCE AND COMBINED COMPOSITION THEREOF | 澳门大学 | 2023-12-28 | — | — | WO | claimed |
| WO-2023227757-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-11-30 | — | — | WO | claimed |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | NADIANBIO LTD. (KR) | 2023-08-17 | — | — | US | claimed |
| CN-115803060-A | Pharmaceutical composition for preventing or treating cancer comprising naphthoquinone-based compound and immune checkpoint inhibitor as active ingredients | (株) 娜迪安生物公司 | 2023-03-14 | — | — | CN | claimed |
| CN-115054608-A | Application of cryptotanshinone substances and combination composition thereof | 澳门大学 | 2022-09-16 | — | — | CN | claimed |
| EP-0888326-B1 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RES FOUND (US) | 2006-08-16 | — | — | EP | claimed |
| JP-2000506841-A | — | — | 2000-06-06 | — | — | JP | claimed |
| US-5886027-A | DUNNIONE A PLANT EXTRACT OBTAINABLE FROM STREPTOCARPUS DUNNII OR CALCEOLARIA INTEGRIFOLIA | BTG INTERNATIONAL LIMITED (GB) | 1999-03-23 | — | — | US | claimed |
| CN-1206331-A | Fungicidal compounds | BRITISH TECH GROUP (GB) | 1999-01-27 | — | — | CN | claimed |
| EP-0888326-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1999-01-07 | — | — | EP | claimed |
| EP-0861028-A1 | FUNGICIDAL COMPOUNDS (B) | BTG INTERNATIONAL LIMITED (GB) | 1998-09-02 | — | — | EP | claimed |
| WO-1997031936-A2 | NOVEL ORTHO-NAPHTHOQUINONE DERIVATIVES, NOVEL SYNTHESIS THEREFOR, AND THEIR USE IN THE INHIBITION OF NEOPLASTIC CELL GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1997-09-04 | — | — | WO | claimed |
| WO-1997016970-A1 | FUNGICIDAL COMPOUNDS (B) | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1997-05-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358731-A1 | SUMO PATHWAY AS AN OXYGEN SENSOR RELEVANT TO THE PATHOPHYSIOLOGY OF PULMONARY ARTERY HYPERTENSION AND CARDIAC ARRHYTHMIA | SUMO1, SUMO2, SUMO3 | NQO1 2652/4885POR 1532/4885MEN1 4082/4885 |
| US-20230255904-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING NAPHTHOQUINONE-BASED COMPOUND AND IMMUNE CHECKPOINT INHIBITOR AS ACTIVE INGREDIENTS | PDCD1, CD274, PDCD10 | NQO1 17/4885POR 3903/4885MEN1 1409/4885 |
| US-20250170252-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | NQO1, SQOR, GSTP1 | NQO1 1/4885POR 198/4885MEN1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.